In vivo dosimetry and seed localization in prostate brachytherapy with permanent implants

Rosenfeld, A.B.; Cutajar, D.L.; Lerch, Michael L. F; Takacs, George J.; Brady, Josephine; Braddock, T.; Pervertailo, V.; Bucci, J.; Kersley, J.; Zaider, Marco; Zeléfsky, Michael J.

doi:10.1109/nssmic.2003.1352182

Cited by 5 publications

(5 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous investigations of the concept of spectroscopic dosimetry by Cutajar et al [10,11] determined spectroscopic dosimetry to be accurate to within ±2.5 % over the same 50 mm range. The urethral minidosimeter simulations were deemed suitable to be used to model the effects of modifying the urethral mini-dosimeter construction on the dosimetry.…”

Section: Methodsmentioning

confidence: 92%

“…The Centre for Medical Radiation Physics (CMRP) at the University of Wollongong (UOW) in Australia has developed an intra-operative dosimetry system based on in vivo photon spectroscopy [10,11] to accurately measure the dose rate along the urethra LDR prostate brachytherapy. The system is based on a silicon mini detector directly coupled to a novel miniature amplifier system of sub millimetre size within a thin urethral probe.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Monte Carlo validation and optimisation of detector packaging for spectroscopic dosimetry for in vivo urethral dosimetry during low dose rate brachytherapy

Nourbehesht

Cutajar

Guatelli

et al. 2015

Australas Phys Eng Sci Med

View full text Add to dashboard Cite

The urethral mini-dosimeter, developed by the Centre for Medical Radiation Physics, University of Wollongong, uses spectroscopic dosimetry to provide real time point dose measurements along the urethra during low dose rate prostate brachytherapy. Spectroscopic dosimetry uses the measured spectrum of the treatment isotope to estimate the dose rate at the point of measurement, however, the silicon mini-detectors employed in the urethral mini-dosimeter require water proof encapsulation which must be capable of providing electromagnetic shielding without greatly increasing the size of the probe. The introduction of non-tissue equivalent materials within the encapsulation can change the spectrum of radiation incident on the detector, which may influence the application of spectroscopic dosimetry within the urethral dosimeter. The Monte Carlo code Geant4 was adopted to study the effect of encapsulation on the operation of the urethral mini-dosimeter, as well as to determine whether an appropriate thickness of aluminium shielding was possible for electromagnetic screening. The depth dose response and angular dependence of the urethral mini-dosimeter with three thicknesses of aluminium shielding (20, 50, 100 µm) was compared with the urethral mini-dosimeter without aluminium shielding. The aluminium shielding had the effect of increasing the depth dose response (up to 3% within 30 mm and up to 5% within 50 mm), slightly reduced the azimuth angular dependence and slightly increased the polar angular dependence. The 100 µm thick shielding provided the least azimuth angular dependence (±2 %) and provided a polar angular dependence of ±1.4 % within the angles of -45° to 45°.

show abstract

Section: Methodsmentioning

confidence: 92%

Section: Introductionmentioning

confidence: 99%

Monte Carlo validation and optimisation of detector packaging for spectroscopic dosimetry for in vivo urethral dosimetry during low dose rate brachytherapy

Nourbehesht

Cutajar

Guatelli

et al. 2015

Australas Phys Eng Sci Med

View full text Add to dashboard Cite

show abstract

“…Occasional IVD feasibility studies have also been conducted in some clinics. [12][13][14][15][16][17][18][19][20][21][22][23][24] However, routine implementations of IVD for error detection monitoring and QA of the BT treatments is yet to come. One reason for this may be that the cost vs benefit relation of IVD is not established and that robust IVD systems that do not leave a significant footprint on the treatment workflow are not commercially available.…”

Section: Treatment Errors In Btmentioning

confidence: 99%

In vivodosimetry: trends and prospects for brachytherapy

Kertzscher¹,

Rosenfeld²,

Beddar³

et al. 2014

BJR

View full text Add to dashboard Cite

The error types during brachytherapy (BT) treatments and their occurrence rates are not well known. The limited knowledge is partly attributed to the lack of independent verification systems of the treatment progression in the clinical workflow routine. Within the field of in vivo dosimetry (IVD), it is established that real-time IVD can provide efficient error detection and treatment verification. However, it is also recognized that widespread implementations are hampered by the lack of available high-accuracy IVD systems that are straightforward for the clinical staff to use. This article highlights the capabilities of the state-of-the-art IVD technology in the context of error detection and quality assurance (QA) and discusses related prospects of the latest developments within the field. The article emphasizes the main challenges responsible for the limited practice of IVD and provides descriptions on how they can be overcome. Finally, the article suggests a framework for collaborations between BT clinics that implemented IVD on a routine basis and postulates that such collaborations could improve BT QA measures and the knowledge about BT error types and their occurrence rates.

show abstract

“…We have developed a probe which measures in real time the dose delivered along the urethra and may be used by the physicians during seed implantation to monitor for excessive doses. In vivo dosimetry is commonly performed with miniature radiation detectors such as MOSFETs or diodes 1) . The main disadvantages of such systems are energy dependence and low sensitivity.…”

Section: Introductionmentioning

confidence: 99%

Urethral Alarm Probe for Permanent Prostate Implants

Cutajar¹,

Lerch²,

Takacs³

et al. 2008

Journal of Nuclear Science and Technology

Self Cite

View full text Add to dashboard Cite

We have developed a urethral dosimetry system for real time dose verification along the urethra during permanent implant prostate brachytherapy. The urethral alarm probe uses "spectroscopic dosimetry" to calculate the dose rate along the urethra in real time. The application of spectroscopic dosimetry for the urethral alarm probe was verified using Monte Carlo calculations. In phantom depth dose measurements as well as isotropy measurements were performed to verify the usefulness of the urethra alarm probe as an in vivo real time dosimeter.

show abstract

In vivo dosimetry and seed localization in prostate brachytherapy with permanent implants

Cited by 5 publications

References 15 publications

Monte Carlo validation and optimisation of detector packaging for spectroscopic dosimetry for in vivo urethral dosimetry during low dose rate brachytherapy

Monte Carlo validation and optimisation of detector packaging for spectroscopic dosimetry for in vivo urethral dosimetry during low dose rate brachytherapy

In vivodosimetry: trends and prospects for brachytherapy

Urethral Alarm Probe for Permanent Prostate Implants

Contact Info

Product

Resources

About